For people 2 years of age and older with active psoriatic arthritis
COSENTYX® (secukinumab) is the #1 prescribed* and first biologic treatment of its kind.†
†Treatment for PsA that targets IL-17A, one of the multiple molecules in the body that may play a role in inflammation.
Watch the video to see how COSENTYX is thought to work to help people with psoriatic arthritis (PsA).§
Did you know an overactive immune system is like an overactive tennis ball machine? There are multiple molecules in the body that may play a role in causing inflammation. The IL-17A molecule is just one of them.
Patient portrayal of how COSENTYX works.
§The relationship between how COSENTYX works in the body and how it affects your symptoms is unknown.
How does COSENTYX work?
COSENTYX is a different kind of targeted biologic. It's the first and most prescribed treatment of its kind¶ and works within your body to target IL-17A. IL-17A is one of the multiple molecules in the body that may play a role in causing inflammation. It’s the first and only treatment to offer both self-injection and IV infusion dosing options that target IL-17A.
What is a biologic?
A biologic is a protein-based medication that is made from living sources, and is taken by injection or infusion.
¶Across all indications combined.
If left untreated, psoriatic arthritis can cause permanent joint damage, also known as radiographic progression
Psoriatic arthritis (PsA) symptoms can progress and your joints, such as your fingers or toes, can become permanently damaged. This can disrupt your ability to perform daily activities. COSENTYX is proven to help stop further joint damage.
In the largest clinical trial ever conducted for psoriatic arthritis, COSENTYX was proven to help stop further joint damage#, ||,**
77% of adults taking COSENTYX had no increase in joint damage at 6 months††
#Based on data from X-rays of the hands and feet at 6 months.
||Administered subcutaneously (under your skin).
**All results shown in clinical trials using subcutaneous (SC) administration (injection under the skin). The FDA approval of the intravenous (IV) administration (injected into a vein) of COSENTYX is based on data showing that the amount of the medication in your body after it is given directly through IV was within the range that would be seen when given as SC.
††For adults taking the 300-mg dose of COSENTYX. 71% of patients had no increase in joint damage at 6 months in the 150-mg group, versus 68% of patients taking placebo.
Individual results may vary. Darren was compensated for his time.
“I had a lot of swollen joints and psoriasis flakes all over. It was hard to get up in the morning and get ready. With COSENTYX, I started looking and feeling better in a short time. And since then, I’m doing the things I want to do with much less pain.”
GET RESULTS FAST THAT CAN LAST
Complete reduction of swelling
In a clinical trial, more than half of adults with completely swollen fingers and toes (dactylitis) no longer had signs of swelling after 6 months of taking COSENTYX versus 15% for placebo.